In animal models, the use of different c-Abl inhibitors has been shown to improve motor behavior in animals and prevent loss of dopaminergic neurons [1,35], while the inhibitors Nilotinib and Radontinib even showed improvement in motor and cognitive symptoms in PD patients [35]. The gene discussed is ABL1; the disease is Parkinson disease.